Mayes Stacey, Ferrone Marcus
Baptist Medical Center Downtown and Wolfson Children's Hospital, Jacksonville, FL 32207, USA.
Ann Pharmacother. 2006 Dec;40(12):2178-86. doi: 10.1345/aph.1H135.
To summarize the pharmaceutics, pharmacokinetics, development, and clinical application of IONSYS, the fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain.
Clinical literature including both primary sources and review articles was accessed through a search of the MEDLINE databases (1980-October 2006). Key search terms included cutaneous analgesia, fentanyl, IONSYS, opioid, postoperative pain, and patient-controlled analgesia (PCA). Additional clinical trial and drug data were supplied by the manufacturer, the ALZA Corporation.
Review articles, abstracts, and clinical studies related to patient-controlled iontophoretic transdermal fentanyl and postoperative pain management were analyzed. An evaluation of the research exploring IONSYS for the management of acute postoperative pain was conducted. Relevant information was then selected and is provided in this article.
IONSYS is the first iontophoretic transdermal drug delivery system that utilizes low-level electrical energy to actively transport ionized fentanyl HCl through intact skin. Research has revealed that use of IONSYS for patients with acute postoperative pain is safe, effective, and well tolerated. Phase I-III trials have demonstrated an appropriate dosing range leading to effective analgesia, with minimal adverse effects. The analgesia provided by this system was found to be superior to that of analgesia placebo and equivalent to that of an intravenous morphine PCA.
Data from clinical trials indicated that IONSYS is successful in controlling acute postoperative pain that circumvents the limitations of intravenous patient-controlled analgesia. The use of this system may serve as an alternative modality for the management of acute pain without increasing such adverse effects as bleeding, intravenous catheter infiltration, or manual pump malfunction.
总结IONYSYS(用于术后急性疼痛管理的盐酸芬太尼患者自控离子电渗透皮给药系统)的药剂学、药代动力学、研发情况及临床应用。
通过检索MEDLINE数据库(1980年至2006年10月)获取包括原始资料和综述文章在内的临床文献。关键检索词包括皮肤镇痛、芬太尼、IONYSYS、阿片类药物、术后疼痛和患者自控镇痛(PCA)。其他临床试验和药物数据由制造商阿尔扎公司提供。
分析与患者自控离子电渗透皮芬太尼及术后疼痛管理相关的综述文章、摘要和临床研究。对探索IONYSYS用于术后急性疼痛管理的研究进行评估。然后选择相关信息并在本文中提供。
IONYSYS是首个利用低水平电能将离子化盐酸芬太尼主动透过完整皮肤进行输送的离子电渗透皮给药系统。研究表明,IONYSYS用于术后急性疼痛患者安全、有效且耐受性良好。I - III期试验已证明其有合适的给药范围,可产生有效的镇痛效果,且不良反应最小。该系统提供的镇痛效果优于镇痛安慰剂,与静脉注射吗啡PCA相当。
临床试验数据表明,IONYSYS成功控制了术后急性疼痛,克服了静脉注射患者自控镇痛的局限性。使用该系统可作为急性疼痛管理的替代方式,而不会增加出血、静脉导管渗漏或手动泵故障等不良反应。